Medicine · 2018
Long-term clinical response of advanced lung adenocarcinoma to maintenance treatment of gemcitabine: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lv Xingxing, Gou Fusheng, Shen Yuan, Lu Hong, Chen Juan, Liu Juan, Chen Hui, Zhang Xuan, Yu Danfei
Аннотация
RATIONALE: Advanced non-small-cell lung cancer (NSCLC) is an aggressive malignancy that generally leads to poor outcomes, with <5% long-term survival at 5 years; however, several researches have shown improvements in the progression-free survival (PFS) and overall survival (OS) on the maintenance therapy after the first-line chemotherapy. we report a case of metastatic NSCLC patient treated with maintenance therapy of gemcitabine with brilliant results.
PATIENT CONCERNS: Clinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study.
DIAGNOSIS: Lung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation.
INTERVENTIONS: Continued treatment with gemcitabine alone following the 6 cycles of cisplatin-gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug.
OUTCOMES: Partial response of the disease for 4.5 years and significant clinical benefit.
LESSONS: This case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.
PATIENT CONCERNS: Clinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study.
DIAGNOSIS: Lung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation.
INTERVENTIONS: Continued treatment with gemcitabine alone following the 6 cycles of cisplatin-gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug.
OUTCOMES: Partial response of the disease for 4.5 years and significant clinical benefit.
LESSONS: This case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.